[Tacrolimus in diseases other than atopic dermatitis].
Topical tacrolimus is an immunosuppressant that acts through the inhibition of calcineurin and thus of the T cells. This causes a decrease in the production of interleukins, the granulocyte colony stimulating factor, alpha interferon and tumor necrosis factor. Although the use of topical tacrolimus is only indicated for the treatment of moderate or severe atopic dermatitis, its immunosuppressant effect and fewer side effects regarding topical corticosteroids have lead to the increase of its use in other types of inflammatory skin diseases. The purpose of this article is to review the use of tacrolimus in this group of diseases other than atopic dermatitis, this use not being authorized within the data sheet of the drug.
Alomar
A
A
Servicio de Dermatología, Hospital de Sant Pau, Barcelona, España. Aalomar@santpau.es
Corella
F
F
García-Navarro
X
X
D000328:Adult; D001327:Autoimmune Diseases / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017512:Lichenoid Eruptions / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D056687:Off-Label Use; D011537:Pruritus / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000627:therapeutic use*; D014511:Uremia / Q000150:complications; D014820:Vitiligo / Q000188:drug therapy
D007166:Immunosuppressive Agents; D016559:Tacrolimus